Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEVEN J ROSENBERG

Allopathic & Osteopathic Physicians Urology

NPI
1861488785
CMS profile
311678
Location
URBANDALE, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$35.06

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $35.06 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $35.06 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEVEN J ROSENBERG

NPI 1861488785 · CMS profile ID 311678

Allopathic & Osteopathic Physicians / Urology

URBANDALE, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861488785?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861488785?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861488785?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
STEVEN J ROSENBERG, NPI 1861488785, CMS profile ID 311678, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1861488785?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $35.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $35.0611/19/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1206321420 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $91.52 2
PY2020 $114.16 4
PY2021 $104.92 4
PY2022 $197.25 10
PY2023 $327.28 13
PY2024 $262.96 10
PY2025 $35.06 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $12,321.51 2
PY2023 Principal investigator $130,788.17 20
PY2022 Principal investigator $127,711.29 38
PY2021 Principal investigator $137,948.28 39
PY2020 Principal investigator $320,867.55 65
PY2019 Principal investigator $602,559.33 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

38 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 12/24/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 965505609
Principal investigator 1 Dendreon Pharmaceuticals LLC $9,764.82 11/25/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 943787667
Principal investigator 1 Janssen Research & Development, LLC $4,829.00 11/14/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multi Center Open label Single arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy ADT in Treatment naive Participants Who Have Undergone Radical Prostatectomy RP for Nonmetastatic Prostate Cancer and Who Are at High Risk for Metastases No dispute reported 06/30/2026 885240215
Principal investigator 1 Astellas Pharma Global Development $23,556.00 11/09/2022 Non-covered Recipient Entity
The Iowa Clinic, P.C.
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1021946787
Principal investigator 1 UROVANT SCIENCES INC $201.80 11/09/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445653
Principal investigator 1 UROVANT SCIENCES INC $9,194.40 11/09/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445657
Principal investigator 1 UROVANT SCIENCES INC $1,000.00 10/19/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445661
Principal investigator 1 UROVANT SCIENCES INC $575.00 10/19/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445663
Principal investigator 1 UROVANT SCIENCES INC $500.00 10/19/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445667
Principal investigator 1 UROVANT SCIENCES INC $1,500.00 10/19/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445671
Principal investigator 1 Astellas Pharma Global Development $3,946.00 10/12/2022 Non-covered Recipient Entity
The Iowa Clinic, P.C.
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1021946777
Principal investigator 1 UROVANT SCIENCES INC $120.00 10/05/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445649
Principal investigator 1 UROVANT SCIENCES INC $1,200.00 08/29/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) No dispute reported 06/30/2026 926444371
Principal investigator 1 UROVANT SCIENCES INC $526.50 07/15/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926444129
Principal investigator 1 UROVANT SCIENCES INC $700.00 07/13/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926444133
Principal investigator 1 UROVANT SCIENCES INC $700.00 07/13/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926444292
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 07/02/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943941915
Principal investigator 1 GlaxoSmithKline, LLC. $700.00 07/02/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943941917
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 06/24/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE III, RANDOMIZED, MULTICENTER, PARALLEL-GROUP, DOUBLE-BLIND, DO No dispute reported 06/30/2026 943941913
Principal investigator 1 Janssen Research & Development, LLC $3,548.00 06/22/2022 Non-covered Recipient Entity
The Ia Clnc
A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer No dispute reported 06/30/2026 885223937
Principal investigator 1 UROVANT SCIENCES INC $680.40 06/22/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445565
Principal investigator 1 Janssen Research & Development, LLC $2,500.00 05/30/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Multi Center Open label Single arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy ADT in Treatment naive Participants Who Have Undergone Radical Prostatectomy RP for Nonmetastatic Prostate Cancer and Who Are at High Risk for Metastases No dispute reported 06/30/2026 885240211
Principal investigator 1 Astellas Pharma Global Development $32,108.00 05/12/2022 Non-covered Recipient Entity
The Iowa Clinic, P.C.
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1021946771
Principal investigator 1 Dendreon Pharmaceuticals LLC $1,654.38 05/03/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 943787581
Principal investigator 1 UROVANT SCIENCES INC $30.00 04/27/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445569
Principal investigator 1 UROVANT SCIENCES INC $680.40 04/22/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445561
Principal investigator 1 UROVANT SCIENCES INC $340.20 03/18/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445553
Principal investigator 1 Astellas Pharma Global Development $176.00 03/07/2022 Non-covered Recipient Entity
The Iowa Clinic, P.C.
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1021946793
Principal investigator 1 UROVANT SCIENCES INC $30.00 03/04/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445557
Principal investigator 1 UROVANT SCIENCES INC $340.20 02/23/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445541
Principal investigator 1 Allergan, Inc. $2,000.00 02/01/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Androderm 24-Hr ABPM No dispute reported 06/30/2026 864368701
Principal investigator 1 Allergan, Inc. $1,500.00 02/01/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Androderm 24-Hr ABPM No dispute reported 06/30/2026 864368707
Principal investigator 1 Allergan, Inc. $1,000.00 02/01/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Androderm 24-Hr ABPM No dispute reported 06/30/2026 864368713
Principal investigator 1 Dendreon Pharmaceuticals LLC $130.00 01/25/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 943787473
Principal investigator 1 Dendreon Pharmaceuticals LLC $3,986.19 01/25/2022 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A RANDOMIZED PHASE 3, OPEN-LABEL TRIAL OF SIPULEUCEL-T ADMINISTERED TO PATIENTS ON ACTIVE SURVEILLANCE FOR NEWLY DIAGNOSED PROSTATE CANCER No dispute reported 06/30/2026 943787475
Principal investigator 1 UROVANT SCIENCES INC $8,277.00 01/21/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445549
Principal investigator 1 Astellas Pharma Global Development $5,685.00 01/05/2022 Non-covered Recipient Entity
The Iowa Clinic PC Urology
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 935424331
Principal investigator 1 UROVANT SCIENCES INC $832.00 01/05/2022 Non-covered Recipient Entity
QCARE SITE SERVICES
An Exploratory Phase 2a Study Evaluating the Efficacy and Safety of URO-902 in Subjects With Overactive Bladder and Urge Urinary Incontinence No dispute reported 06/30/2026 926445545